Marstacimab

Summary

Marstacimab (CHEMBL3990039) is an approved antibody (ATC B02BX11); indicated across 4 conditions including hemophilia a and hemophilia b.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: B02BX11
• Indications: 4 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990039
Name	Marstacimab
Type	Antibody
Max phase	4
ATC	B02BX11

Also known as: Hympavzi, Marstacimab, Marstacimab-hncq, PF-06741086, MARSTACIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemophilia A	4	MONDO:0010602	MONDO:0010602
hemophilia B	4	MONDO:0010604	MONDO:0010604

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1	3
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05145127	PHASE3	RECRUITING	Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
NCT05611801	PHASE3	RECRUITING	A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT03938792	PHASE3	COMPLETED	Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
NCT02974855	PHASE2	COMPLETED	PF-06741086 Multiple Dose Study in Severe Hemophilia
NCT03363321	PHASE2	COMPLETED	PF-06741086 Long-term Treatment in Severe Hemophilia
NCT06703606	PHASE1	RECRUITING	A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
NCT02531815	PHASE1	COMPLETED	Dose Escalation Study of PF-06741086 In Healthy Subjects
NCT04878731	PHASE1	COMPLETED	Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia
NCT06992076	Not specified	RECRUITING	Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
NCT07161687	Not specified	ACTIVE_NOT_RECRUITING	A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).